Eli Lilly and Company
LLY · NYSE
- Prev Close
- $1,115.68
- Market Cap
- $1.09T
- Open
- —
- Trailing P/E
- —
- Day Range
- $1,216.94 - $1,138.43
- 52W Range
- $1,249.45 - $623.78
- Forward P/E
- —
- EPS
- —
- Volume
- 3.91M
- Dividend Yield
- —
About Eli Lilly and Company
Eli Lilly is a large-cap pharmaceutical company that earns revenue by discovering, developing, manufacturing and selling prescription medicines. Its recent growth is being driven by strong demand for GLP-1 drugs and other key products, while its pipeline includes olomorasib, which received FDA Breakthrough Therapy designation for advanced pancreatic cancer. The supplied evidence does not provide a segment breakdown or customer mix, so contributions by business line cannot be quantified. Lilly generated $65.2 billion of revenue and $20.6 billion of net income in fiscal 2025, up from $45.0 billion and $10.6 billion, respectively, in 2024.
Notable Price Movement
- Aug 3-7$1,115.682.89%
Eli Lilly fell 8.60%, from $1,220.66 to $1,115.68, declining in every reported session and reaching its lowest close on August 4 as volume rose to 4.10 million shares. The most identifiable company-specific development was the FDA’s Breakthrough Therapy designation for olomorasib in advanced pancreatic cancer, announced Monday, but it did not prevent a 2.4% decline that day. Investors were also positioning ahead of the August 5 earnings release, which was outside the reported trading window. Available evidence does not identify a negative company announcement during the week; the sustained retreat therefore appears driven mainly by pre-earnings positioning and broader reassessment of the stock’s valuation and growth expectations.
Stories & Analysis
Eli Lilly (LLY) Q2 Earnings and Revenues Surpass EstimatesEli Lilly Boosts FY26 Revenue Outlook; Stock Up 5.2% - UpdateEli Lilly And Co. Bottom Line Advances In Q2Eli Lilly And Co. Q2 26 Earnings Conference Call At 10:00 AM ET
